A team led by a New Jersey researcher has been able to slow the course of a rare childhood brain disease by injecting patients with corrective genes, according to a study published Wednesday. Children often die of complications from Canavan disease by age 3, and almost always by 10. But 10 of the 13 study participants have passed age 10, with three in their late teens.
